Developing Better Therapeutics for Better Lives

​

The global antifungal market is expected to exceed $21 billion by 2032, with over $10 billion attributed to treating yeast infections by 2034. Up to 9 M women in U.S. alone and 130 M women worldwide per year have a need for Sano Chemicals lead product to treat recurrent vulvovaginal candidiasis (RVVC). The rise of drug-resistant strains has created an urgent demand for innovative solutions. High mortality rate associated with invasive fungal infections is attributed to limitations in current therapeutic options. Sano Chemicals believes it's uniquely positioned to capture this market by addressing the unmet need for effective, low-toxicity antifungal treatments.

​

​Relatively few classes of antifungals are available for clinical use, and a new class of antifungals like Occidiofungin targeting drug resistant fungal infections would be well received by clinicians. Sano Chemicals is developing Occidiofungin for treating dermal, oral, and invasive fungal infections. Potent antifungal against Cryptococcus, Aspergillus, and Candida (including Candida auris). 

 

Why Invest

​

Invest in the future of antifungal innovation with Sano Chemicals. Your investment will directly support the advancement of Phase 1 and 2 clinical trials for the development of the recurrent vulvovaginal candidiasis (RVVC) drug product using Occidiofungin. Occidiofungin is a first-in-class antifungal that is designed to address drug-resistant fungal infections. Backed by FDA QIDP designation and robust preclinical and clinical data, Sano Chemicals believes it's well-positioned to fulfill the unmet medical need in the women’s health market, pending further clinical trials and commercialization of Occidiofungin.​

​

Risk adjusted valuations for Sano Chemicals lead RVVC product is based on current insurance reimbursement rates for Vivjoa and Brexafemme. The current products for treating RVVC do not meet the medical needs of the millions of women with RVVC. Sano Chemicals aspires to establish itself as a significant player in the treatment of RVVC, contingent on clinical outcomes and market dynamics. With additional capital, Sano Chemicals anticipates completing Phase 2 studies within 1.5 - 2 years, depending on regulatory approvals and operational progress. We aim to pursue licensing terms for our RVVC lead drug product that align with industry benchmarks, including those seen for Brexafemme, subject to successful development and partner negotiations.. Sano Chemicals has several other products in the pipeline that complement company strength and will bring further value to the company.

 

Market Validation

Preclinical and clinical studies indicate Occidiofungin’s potential effectiveness against drug-resistant fungal strains and suggest its scalability for broader healthcare applications such as dermal, oral, and intravenous administration.

​

We view clinical and commercial business development activities as a necessary component of our strategies, and we seek to enhance shareholder value by evaluating business development opportunities both within and complementary to our current business, as well as opportunities that may be new and separate from the development of our existing product candidates.​

​

As we continue our development of product candidates, we intend to either license these product candidates to, or partner with, one or more major pharmaceutical companies at the earliest possible time in their product development. If we do so, we intend for these licensees or partners to pay the costs associated with any remaining development work, regulatory submissions, clinical trials and the manufacturing and marketing of our product candidates.